565 related articles for article (PubMed ID: 18392810)
21. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
Terry AV; Buccafusco JJ
J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
[TBL] [Abstract][Full Text] [Related]
22. Disturbances in neurotransmission processes in aging and age-related diseases.
Ossowska K
Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
[TBL] [Abstract][Full Text] [Related]
23. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimer's disease brain.
Rao JS; Rapoport SI; Kim HW
Transl Psychiatry; 2011 Aug; 1(8):e31. PubMed ID: 22832605
[TBL] [Abstract][Full Text] [Related]
24. Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology.
Klingner M; Apelt J; Kumar A; Sorger D; Sabri O; Steinbach J; Scheunemann M; Schliebs R
Int J Dev Neurosci; 2003 Nov; 21(7):357-69. PubMed ID: 14599482
[TBL] [Abstract][Full Text] [Related]
25. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction.
Zhang W; Bai M; Xi Y; Hao J; Liu L; Mao N; Su C; Miao J; Li Z
Free Radic Biol Med; 2012 Apr; 52(8):1443-52. PubMed ID: 22342520
[TBL] [Abstract][Full Text] [Related]
26. Phospholipase A2 and arachidonic acid in Alzheimer's disease.
Sanchez-Mejia RO; Mucke L
Biochim Biophys Acta; 2010 Aug; 1801(8):784-90. PubMed ID: 20553961
[TBL] [Abstract][Full Text] [Related]
27. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.
Ingram DK; Spangler EL; Iijima S; Ikari H; Kuo H; Greig NH; London ED
Life Sci; 1994; 55(25-26):2037-49. PubMed ID: 7997063
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia.
Dringenberg HC
Behav Brain Res; 2000 Nov; 115(2):235-49. PubMed ID: 11000423
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans.
Sunderland T; Molchan SE; Little JT; Bahro M; Putnam KT; Weingartner H
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S23-6. PubMed ID: 9339269
[TBL] [Abstract][Full Text] [Related]
30. The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer's disease.
Forlenza OV; Schaeffer EL; Gattaz WF
J Neural Transm (Vienna); 2007 Feb; 114(2):231-8. PubMed ID: 17131232
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies.
Auld DS; Kornecook TJ; Bastianetto S; Quirion R
Prog Neurobiol; 2002 Oct; 68(3):209-45. PubMed ID: 12450488
[TBL] [Abstract][Full Text] [Related]
32. Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction.
Schliebs R; Rossner S; Bigl V
Prog Brain Res; 1996; 109():253-64. PubMed ID: 9009714
[TBL] [Abstract][Full Text] [Related]
33. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.
Nyakas C; Granic I; Halmy LG; Banerjee P; Luiten PG
Behav Brain Res; 2011 Aug; 221(2):594-603. PubMed ID: 20553766
[TBL] [Abstract][Full Text] [Related]
34. Integrating cytosolic phospholipase A₂ with oxidative/nitrosative signaling pathways in neurons: a novel therapeutic strategy for AD.
Sun GY; He Y; Chuang DY; Lee JC; Gu Z; Simonyi A; Sun AY
Mol Neurobiol; 2012 Aug; 46(1):85-95. PubMed ID: 22476944
[TBL] [Abstract][Full Text] [Related]
35. α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles.
Medeiros R; Castello NA; Cheng D; Kitazawa M; Baglietto-Vargas D; Green KN; Esbenshade TA; Bitner RS; Decker MW; LaFerla FM
Am J Pathol; 2014 Feb; 184(2):520-9. PubMed ID: 24269557
[TBL] [Abstract][Full Text] [Related]
36. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
[TBL] [Abstract][Full Text] [Related]
37. [Glutamate and Alzheimer's disease].
Gazulla J; Cavero-Nagore M
Rev Neurol; 2006 Apr 1-15; 42(7):427-32. PubMed ID: 16602060
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease and acetylcholine receptors.
Kihara T; Shimohama S
Acta Neurobiol Exp (Wars); 2004; 64(1):99-105. PubMed ID: 15190684
[TBL] [Abstract][Full Text] [Related]
39. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors.
Mota SI; Ferreira IL; Rego AC
Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316
[TBL] [Abstract][Full Text] [Related]
40. Cholinergic markers in elderly patients with early signs of Alzheimer disease.
Davis KL; Mohs RC; Marin D; Purohit DP; Perl DP; Lantz M; Austin G; Haroutunian V
JAMA; 1999 Apr; 281(15):1401-6. PubMed ID: 10217056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
